SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+6.38%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$405M
AUM Growth
+$405M
(+14%)
Cap. Flow
+$12.9M
Cap. Flow
% of AUM
3.18%
Top 10 Holdings %
Top 10 Hldgs %
49.16%
Holding
86
New
12
Increased
27
Reduced
11
Closed
19
Top Buys
| 1 |
Nuvalent
NUVL
|
$23.4M |
| 2 |
Erasca
ERAS
|
$17.9M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.8M |
| 4 |
UroGen Pharma
URGN
|
$9.96M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$8.75M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$78.2M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$7.89M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$5.98M |
| 4 |
Praxis Precision Medicines
PRAX
|
$5.1M |
| 5 |
Solid Biosciences
SLDB
|
$4.83M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $36.9M | 8.71% | 623,628 +57,341 | +10% | +$3.39M |
|
|
2
Nuvalent
NUVL
$5.52B
| $35.3M | 8.33% | 465,710 +307,960 | +195% | +$23.4M |
|
3
Avidity Biosciences
RNA
$5.99B
| $21.1M | 4.99% | 517,734 +28,431 | +6% | +$1.16M |
|
|
4
UroGen Pharma
URGN
$900M
| $18.5M | 4.36% | 1,102,000 +593,413 | +117% | +$9.96M |
|
|
5
Erasca
ERAS
$445M
| $18.4M | 4.35% | 7,816,926 +7,593,081 | +3,392% | +$17.9M |
|
|
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $16.6M | 3.91% | 486,306 +2,334 | +0.5% | +$79.5K |
|
7
Akero Therapeutics
AKRO
$3.74B
| $14.7M | 3.46% | 625,087 +225,138 | +56% | +$5.28M |
|
8
Celldex Therapeutics
CLDX
$1.47B
| $13.9M | 3.27% | 374,910 +75,594 | +25% | +$2.8M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $13.2M | 3.11% | 192,345 +157,538 | +453% | +$10.8M |
|
|
PSTX
10
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $10.5M | 2.49% | 3,607,999 +11,523 | +0.3% | +$33.6K |
|
11
Cogent Biosciences
COGT
$1.69B
| $10.2M | 2.4% | 1,206,214 +169,547 | +16% | +$1.43M |
|
12
Insmed
INSM
$28.8B
| $9.38M | 2.21% | 140,000 +26,384 | +23% | +$1.77M |
|
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.75M | 2.06% | +36,000 | New | +$8.75M |
|
14
Elutia
ELUT
$96.7M
| $7.95M | 1.88% | 1,603,580 +1,525,000 | +1,941% | +$7.56M |
|
15
Corbus Pharmaceuticals
CRBP
$115M
| $7.81M | 1.84% | 172,492 +140,512 | +439% | +$6.36M |
|
16
Oric Pharmaceuticals
ORIC
$994M
| $7.61M | 1.79% | 1,075,812 -37,195 | -3% | -$263K |
|
17
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.6M | 1.79% | +370,000 | New | +$7.6M |
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.58M | 1.79% | 184,662 +886 | +0.5% | +$36.4K |
|
19
C4 Therapeutics
CCCC
$185M
| $6.67M | 1.57% | 1,442,841 +6,910 | +0.5% | +$31.9K |
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $6.64M | 1.57% | +42,000 | New | +$6.64M |
|
21
KalVista Pharmaceuticals
KALV
$678M
| $6.61M | 1.56% | 560,883 -300 | -0.1% | -$3.53K |
|
22
Veracyte
VCYT
$2.39B
| $6.12M | 1.44% | 282,248 +1,475 | +0.5% | +$32K |
|
|
ABVX
23
Abivax
ABVX
$6.12B
| $6.03M | 1.42% | 455,800 +380,800 | +508% | +$5.03M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $5.92M | 1.4% | 546,863 +31,546 | +6% | +$341K |
|
25
ADC Therapeutics
ADCT
$345M
| $5.59M | 1.32% | 1,768,770 +1,267,548 | +253% | +$4.01M |
|